Skip to main content

Advertisement

SpringerLink
Log in

The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The Glasgow Prognostic Score (GPS) serves a prognostic role in several lymphomas. The objectives of the present study were to determine whether GPS predicts clinical outcomes and to compare the utility of four prognostic scores, including GPS, in patients diagnosed with peripheral T-cell lymphoma (PTCL). We selected for this retrospective study 96 patients consecutively diagnosed with PTCL according to the World Health Organization classification from January 2002 to February 2013 and followed up in five different institutions. Low GPS was a good prognostic biomarker of progression-free survival (PFS, P = 0.030) and overall survival (OS, P = 0.013). Estimated 3-year OS rates (low-risk vs. intermediate- or high-risk) by the International Prognostic Index (IPI), the Prognostic Index for T-cell lymphoma (PIT), the International Peripheral T-cell Lymphoma Project (IPTCLP) score, and GPS were 83% vs. 44% (P < 0.001), 68% vs. 37% (P = 0.004), 71% vs. 26% (P < 0.001) and 68% vs. 51% (P = 0.031), respectively. These results indicate that GPS has prognostic value for PTCL. In addition, all four prognostic scores demonstrate their usefulness in assessing PTCL outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–18.

  2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol. 1998;9:717–20.

    Article  CAS  PubMed  Google Scholar 

  3. Harris ME. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.

    Article  Google Scholar 

  4. Armitage JO. The aggressive peripheral T-cell lymphomas. Am J Hematol. 2015;90:665–73.

    Article  PubMed  Google Scholar 

  5. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.

    Article  CAS  PubMed  Google Scholar 

  6. Balkwill F. Mantovani A inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.

    Article  CAS  PubMed  Google Scholar 

  7. Mantovani A, Allavena P, Sica A. Balkwill F cancer-related inflammation. Nature. 2008;454:436–44.

    Article  CAS  PubMed  Google Scholar 

  8. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223–6.

    Article  PubMed  Google Scholar 

  10. Nozoe T, Matono R, Ijichi H, Ohga T, Ezaki T. Glasgow Prognostic Score (GPS) can be a useful indicator to determine prognosis of patients with colorectal carcinoma. Int Surg. 2014;99:512.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Gao Y, Huang D. The value of the systematic inflammation-based Glasgow Prognostic Score in patients with gastric cancer: a literature review. J Cancer Res Ther. 2014;10:799.

    Article  PubMed  Google Scholar 

  12. Partridge M, Fallon M, Bray C, McMillan D, Brown D, Laird B. Prognostication in advanced cancer: a study examining an inflammation-based score. J Pain Symptom Manage. 2012;44:161–7.

    Article  PubMed  Google Scholar 

  13. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534–40.

    Article  PubMed  Google Scholar 

  14. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DSJ, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47:2633–41.

    Article  PubMed  Google Scholar 

  15. Shipp M, Harrington D, Anderson J, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.

    Article  Google Scholar 

  16. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402–8.

    Article  CAS  PubMed  Google Scholar 

  17. Shipp M. A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med. 1993;329:987–94.

    Article  Google Scholar 

  18. Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018;181:760–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Martinez A, Villamor N, Ghita G, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22:397–404.

    Article  CAS  PubMed  Google Scholar 

  20. Kim Y, Kim SJ, Hwang D, Jang J, Hyun SY, Kim YR, et al. The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen. Yonsei Med J. 2014;55:1568–75.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Li X, Zhang Y, Zhao W, Liu Z, Shen Y, Li J, et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol. 2015;94:57–63.

    Article  CAS  PubMed  Google Scholar 

  22. Kanemasa Y, Shimoyama T, Sasaki Y, Sawada T, Omuro Y, Hishima T, et al. A convenient prognostic score consisting of the Glasgow prognostic score and serum lactate dehydrogenase predicts clinical outcome in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57:2460–3.

    Article  PubMed  Google Scholar 

  23. Jung S-H, Yang D-H, Ahn J-S, Kim Y-K, Kim H-J, Lee J-J. Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-Cell lymphoma. Acta Haematol. 2015;133:10–7.

    Article  CAS  PubMed  Google Scholar 

  24. Li YJ, Jiang WQ, Huang JJ, Xia ZJ, Huang HQ, Li ZM. The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type. Am J Hematol. 2013;88:394–9.

    Article  CAS  PubMed  Google Scholar 

  25. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117:104–11.

    Article  CAS  PubMed  Google Scholar 

  26. Raziuddin S, Sheikha A, Abu-Eshy S, Al-Janadi M. Cir45 culating levels of cytokines and soluble cytokine receptors in various T-cell malignancies. Cancer. 1994;73:2426–31.

    Article  CAS  PubMed  Google Scholar 

  27. Wang J, Zhou M, Wang X, Xu J, Chen B, Ouyang J. Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP. Clin Chim Acta. 2016;459:150–4.

    Article  CAS  PubMed  Google Scholar 

  28. Adams HJ, De Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, et al. Prognostic value of anemia and C-reactive protein levels in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15:671–9.

    Article  PubMed  Google Scholar 

  29. Gage JR, Fonarow G, Hamilton M, Widawski M, Martínez-Maza O, Vredevoe DL. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. NeuroImmunoModulation. 2004;11:173–80.

    Article  CAS  PubMed  Google Scholar 

  30. Gortney JS, Sanders RM. Impact of C-reactive protein on treatment of patients with cardiovascular disease. Am J Health Syst Pharm. 2007;64:2009–16.

    Article  CAS  PubMed  Google Scholar 

  31. Koukourakis MI, Kambouromiti G, Pitsiava D, Tsousou P, Tsiarkatsi M, Kartalis G. Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. Inflammation. 2009;32:169–75.

    Article  CAS  PubMed  Google Scholar 

  32. Lee C, Adler A, Sandhu M, Sharp S, Forouhi N, Erqou S, et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia. 2009;52:1040–7.

    Article  CAS  PubMed  Google Scholar 

  33. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19:958–63.

    Article  CAS  PubMed  Google Scholar 

  35. Jantunen E, d’Amore F. Stem cell transplantation for peripheral T-cell lymphomas. Leuk Lymphoma. 2004;45:441–6.

    Article  PubMed  Google Scholar 

  36. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20:1533–8.

    Article  CAS  PubMed  Google Scholar 

  37. Rüdiger T, Weisenburger D, Anderson J, Armitage J, Diebold J, MacLennan K, et al. Non-Hodgkin’s Lymphoma Classification Project: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13:140–9.

    Article  PubMed  Google Scholar 

  38. Vose J, The International PTCL Project. International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood. 2005;2005(106):611–3.

    Google Scholar 

  39. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115:1026–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Dong-A University Research Fund.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Dong-A University College of Medicine, 26 Daeshingongwon-ro, Seo-gu, Busan, 49201, South Korea

    Seok Jae Huh, Sung Yong Oh, Suee Lee, Ji Hyun Lee, Sung Hyun Kim & Hyo-Jin Kim

  2. Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, South Korea

    Gyeong-Won Lee

  3. Department of Medicine, Samsung Medical Center, Seoul, South Korea

    Seok Jin Kim & Won Seog Kim

  4. Department of Internal Medicine, Kosin University Gospel Hospital, Busan, South Korea

    Ho Sup Lee

  5. Department of Hematology and Oncology, University of Ulsan College of Medicine, 877 Bangeojinsunhwando-ro, Don-gu, Ulsan, 44033, South Korea

    Jae-Cheol Jo

  6. Division of Hematology-Oncology, Department of Medicine, Myongji Hospital, Goyang-si, Gyeonggido, South Korea

    Moon Jin Kim

  7. Department of Internal Medicine, Kangdong Sacred Heart Hospital, Seoul, South Korea

    Jung Hye Kwon

Authors
  1. Seok Jae Huh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sung Yong Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suee Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ji Hyun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sung Hyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gyeong-Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Seok Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Won Seog Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ho Sup Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jae-Cheol Jo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Moon Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jung Hye Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hyo-Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Sung Yong Oh or Jae-Cheol Jo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huh, S.J., Oh, S.Y., Lee, S. et al. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. Int J Hematol 110, 438–446 (2019). https://doi.org/10.1007/s12185-019-02693-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-019-02693-z

Keywords

Search

Navigation